… O) will complement anti-tumor activity of immune checkpoint blocking antibody, durvalumab
(D), in mCRPC (NCT02484404). Methods: Single arm pilot study with accrual of 25 patients (…

… /m 2 every 3 weeks for phase 2 study. Here, we report the results of a phase 2 clinical trial
among … Outcomes were assessed according to Prostate Cancer Working Group 2 (PCWG2) 17 …

… Through this phase I clinical trial, we aimed to stimulate a potent, immune system-mediated,
antitumor effect by transfecting the IL-2 gene directly into the prostate tumor. Evidence …

… phase 2 trial of 207 homogenously treated patients with prostate cancer, yielding a 5-year
actuarial prostate-… %, minimal (<3%) grade 2 late urinary and rectal toxic effects, and excellent …

… This study demonstrates a definite clinical response of androgen-independent prostate
cancer to APC immunotherapy. Currently we are studying this mode of therapy in Phase 3 trials. …

… Several studies have shown metformin to be safe in patients without diabetes mellitus, and
… This phase 2 trial conducted by the Swiss Group for Clinical Cancer Research investigates …

… Other in vitro studies have suggested increased sensitivity to mTOR inhibition in tumors
with … This phase 2 study conducted by the Swiss Group for Clinical Cancer Research …

… In this multicenter prospective phase 2 study, we demonstrate that 99m Tc-trofolastat ( 99m
Tc-MIP1404) SPECT/CT imaging is able to detect varying degrees of primary PCa with high …

… , a 2-weekly regimen has not been compared with 3-weekly docetaxel as first-line cytotoxic
therapy for advanced prostate cancer … prostate cancer: updated survival in the TAX 327 study. …

… serum prostate-specific antigen (PSA) and circulating tumor cells (CTCs). To further assess
PSMA ADC, we conducted a phase 2 trial in metastatic castration-resistant prostate cancer (…